This publication compiles data generated by proteomics and metabolomics about psychiatric disorders. Leading researchers in these fields review the basic principles of proteomics and metabolomics and propose the new directions to be followed in molecular psychiatry. The chapters divided into two sections - Schizophrenia/Psychotic Disorders and Mood Disorders - deal with findings in diverse tissues from human and preclinical models in order to unravel the biology and biochemistry behind the establishment and course of these illnesses as well as potential biomarkers for clinical applications. More than an update, this publication indicates the next steps to discover biomarkers and understand psychiatric disorders more comprehensively. This publication is valuable reading for psychiatrists, neuroscientists and analytical chemists interested in the basics of proteomics and metabolomics, psychiatric definitions and the most advanced hypotheses about the pathobiology of schizophrenia, depression and bipolar disorder.
128 - 138: Use of Metabolomics and Proteomics to Reveal Pathophysiological Pathways in Anxiety Disorders
Elisabeth Altmaier, Rebecca T. Emeny, 2014. "Use of Metabolomics and Proteomics to Reveal Pathophysiological Pathways in Anxiety Disorders", Proteomics and Metabolomics in Psychiatry, D. Martins-de-Souza
Download citation file: